Zsombor Zrubka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3349691/publications.pdf

Version: 2024-02-01

840776 752698 44 500 11 20 citations h-index g-index papers 54 54 54 537 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Current Medical Research and Opinion, 2016, 32, 829-834.	1.9	100
2	Psychometric properties of the Hungarian version of the eHealth Literacy Scale. European Journal of Health Economics, 2019, 20, 57-69.	2.8	49
3	State of the Art in Adoption of Contact Tracing Apps and Recommendations Regarding Privacy Protection and Public Health: Systematic Review. JMIR MHealth and UHealth, 2021, 9, e23250.	3.7	48
4	The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. European Journal of Health Economics, 2019, 20, 5-16.	2.8	22
5	Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Markers of Survival in Patients with Head and Neck Tumours—Results of a Retrospective Multicentric Study. International Journal of Environmental Research and Public Health, 2020, 17, 1742.	2.6	21
6	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 537-549.	1.4	19
7	A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. European Journal of Health Economics, 2019, 20, 119-132.	2.8	17
8	Outcomes of Digital Biomarker–Based Interventions: Protocol for a Systematic Review of Systematic Reviews. JMIR Research Protocols, 2021, 10, e28204.	1.0	17
9	Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study. Journal of Medical Internet Research, 2020, 22, e19013.	4.3	17
10	The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases. Current Pharmaceutical Design, 2018, 23, 6770-6778.	1.9	14
11	Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data. Quality of Life Research, 2020, 29, 2863-2874.	3.1	13
12	Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. European Journal of Health Economics, 2019, 20, 141-154.	2.8	12
13	Thrombocytosis and Effects of IL-6 Knock-Out in a Colitis-Associated Cancer Model. International Journal of Molecular Sciences, 2020, 21, 6218.	4.1	12
14	Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary. European Journal of Health Economics, 2019, 20, 17-30.	2.8	11
15	Health Economic Publications From the Middle East and North Africa Region: A Scoping Review of the Volume and Methods of Research. Global Journal on Quality and Safety in Healthcare, 2020, 3, 44-54.	0.5	10
16	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. Rheumatology International, 2017, 37, 1957-1977.	3.0	9
17	PP424 Piloting A Comprehensive Search For eHealth Definitions In The Grey Literature: Preliminary Results From A Systematic Scoping Review. International Journal of Technology Assessment in Health Care, 2021, 37, 36-36.	0.5	9
18	Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability. Pharmacoeconomics, 2022, 40, 587-599.	3.3	9

#	Article	IF	CITATIONS
19	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. European Journal of Health Economics, 2019, 20, 109-117.	2.8	8
20	Predicting Patient-Level 3-Level Version of EQ-5D Index Scores From a Large International Database Using Machine Learning and Regression Methods. Value in Health, 2022, 25, 1590-1601.	0.3	8
21	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Na \tilde{A} -ve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. Advances in Therapy, 2019, 36, 721-745.	2.9	7
22	Validation of the PAM-13 instrument in the Hungarian general population 40Âyears old and above. European Journal of Health Economics, 2022, 23, 1341-1355.	2.8	7
23	Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS. European Journal of Health Economics, 2019, 20, 31-41.	2.8	6
24	Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving. Pharmacoeconomics, 2020, 38, 633-643.	3.3	6
25	Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. Quality of Life Research, 2021, 30, 629-641.	3.1	6
26	Development of Population Tariffs for the ICECAP-A Instrument for Hungary and their Comparison With the UK Tariffs. Value in Health, 2021, 24, 1845-1852.	0.3	6
27	Measuring the acceptability of EQ-5D-3L health states for different ages: a new adaptive survey methodology. European Journal of Health Economics, 2022, 23, 1243-1255.	2.8	5
28	Comparing the measurement properties of the ICECAP-A and ICECAP-O instruments in ages 50–70: a cross-sectional study on a representative sample of the Hungarian general population. European Journal of Health Economics, 2021, 22, 1453-1466.	2.8	4
29	Acceptable health and ageing: results of a cross-sectional study from Hungary. Health and Quality of Life Outcomes, 2020, 18, 346.	2.4	3
30	Risk stratification in endoscopic type I. tympanoplasty. European Archives of Oto-Rhino-Laryngology, 2021, 278, 4757-4766.	1.6	3
31	Self-Reported Waiting Times for Outpatient Health Care Services in Hungary: Results of a Cross-Sectional Survey on a National Representative Sample. International Journal of Environmental Research and Public Health, 2021, 18, 2213.	2.6	3
32	A8.31â€Authorised manufacturing changes of therapeutic monoclonal antibodies in EPAR documents. Annals of the Rheumatic Diseases, 2015, 74, A94.1-A94.	0.9	2
33	Comparing actuarial and subjective healthy life expectancy estimates: A cross-sectional survey among the general population in Hungary. PLoS ONE, 2022, 17, e0264708.	2.5	2
34	EQ-5D Studies in Rheumatology in Eight Central and Eastern European Countries. Value in Health, 2016, 19, A542.	0.3	1
35	PMS3 - INFLIXIMAB FOR DISEASE-MODIFYING ANTI-RHEUMATIC DRUG-NAIVE RHEUMATOID ARTHRITIS PATIENTS: SYSTEMATIC REVIEW AND DESCRIPTIVE ANALYSIS OF PUBLICATIONS OF RANDOMIZED CONTROLLED TRIALS. Value in Health, 2018, 21, S288.	0.3	1
36	PMU90 - HEALTH PROBLEMS IN HUNGARIAN ELDERLY OUTPATIENTS MEASURED BY THE EQ-5D-3L: COMPARISON WITH A POPULATION NORM FOR CENTRAL EASTERN EUROPE. Value in Health, 2018, 21, S323.	0.3	1

#	Article	IF	CITATIONS
37	A biotechnológia hazánkban. Hungarian Statistical Review, 2021, 99, 512-540.	0.1	1
38	Costs of Infection Control and Special Challenges during the Covid-19 Pandemic: Experiences in a Military Hospital. Academic and Applied Research in Military and Public, 2021, 20, 95-110.	0.1	1
39	Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. Musculoskeletal Science and Practice, 2021, 55, 102420.	1.3	1
40	Eq-5d Studies In Nervous System Diseases In Eight Central And Eastern European Countries. Value in Health, 2016, 19, A471.	0.3	0
41	EQ-5D Studies in Diseases of The Circulatory System in Eight Central and Eastern European Countries. Value in Health, 2016, 19, A657-A658.	0.3	O
42	Economic aspects of biosimilar competition in Hungary $\hat{a}\in$ " The treatment of rheumatic disorders. Society and Economy, 2017, 39, 271-290.	0.3	0
43	Applicability Of The EQ-5D-3L Descriptive System To Explore Subjective Future Health Expectations. Value in Health, 2017, 20, A690.	0.3	O
44	PRM171 - DETERMINANTS OF THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES: EXPLORING A NEW APPLICATION OF THE EQ VAS. Value in Health, 2018, 21, S385.	0.3	0